On Jun 23, 2021 Adela closed a Series A round and raised $60,000,000 from Decheng Capital, Deerfield Management, F-Prime Capital, OrbiMed, RA Capital Management, featuring lead investors F-Prime Capital.

About the company: Adela is located at Canada, North America. “Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test.”

Company website: www.adelabio.com